Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edesa Biotech, Inc.EDSA · Entity 7223 | President | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edesa Biotech, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 291,479 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 64,609 · Balance 291,479 F1: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 29, 2026 21:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 64,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-003801 · ownership.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,479 F1 · shares: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date. F1 · price: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date. Read SEC document |
| February 26, 2026 Filed Mar 11, 2026 21:02 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 2,000 | $1.57 | $3,140.00 |
DisclosureSEC source: 0001171843-26-001490 · ownership.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,870 Read SEC document |
| May 29, 2025 Filed Jun 3, 2025 01:18 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 207,201 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-25-003587 · ownership.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,870 F1 · shares: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, of which (i) 142,592 shares shall vest in equal proportions over eighteen (18) months, commencing on the grant date and (ii) 64,609 shares vest in equal proportions over thirty-six (36) months, commencing on the grant date. F1 · price: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, of which (i) 142,592 shares shall vest in equal proportions over eighteen (18) months, commencing on the grant date and (ii) 64,609 shares vest in equal proportions over thirty-six (36) months, commencing on the grant date. F2 · balance_after: Shares reported reflect a 1-for-7 reverse share split effective October 11, 2023. Read SEC document |
| August 04, 2023 Filed Aug 4, 2023 20:18 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 93,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-23-010167 · section16.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,680 F1 · price: Reflects a grant of restricted share units ("RSUs"), which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan. These RSUs represent awards received in lieu of a portion of Reporting Person's cash bonus earned for the calendar year ending December 31, 2022. The number of RSUs was determined by dividing such portion of the cash bonus by the 5-day volume weighted average price (VWAP) of the Issuer's common shares through July 31, 2023. Read SEC document |
| July 20, 2023 Filed Jul 21, 2023 20:31 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantShare Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001654954-23-009533 · section16.xml · derivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Shares · 80,000 shares Expires 2023-07-20 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 36 months beginning on the date of grant. Read SEC document |
| July 20, 2023 Filed Jul 24, 2023 20:46 UTC Amendment | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantShare Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001654954-23-009601 · section16.xml · derivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Shares · 80,000 shares Expires 2033-07-20 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 36 months beginning on the date of grant. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 19:27 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Share Warrants (Right to Buy) · Derivative | 2,119 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0001654954-22-014747 · section16.xml · derivative · entry 3 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,119 Underlying: Common Shares · 2,119 shares Expires not disclosed F3 · security: Consists of Class B Warrants to purchase Common Shares.The Class B Warrants are exercisable on the Initial Exercise Date and will expire 12 months after the Initial Exercise Date. F1 · price: The reported securities are included within 4,239 Common Shares purchased by the reporting person for $1.1250 per Common Share. Each Common Share includes the purchase of one-half of a Class A Warrant to purchase one Common Share, and one-half of a Class B Warrant to purchase one Common Share. F3 · derivative.exercise_date: Consists of Class B Warrants to purchase Common Shares.The Class B Warrants are exercisable on the Initial Exercise Date and will expire 12 months after the Initial Exercise Date. F3 · derivative.expiration_date: Consists of Class B Warrants to purchase Common Shares.The Class B Warrants are exercisable on the Initial Exercise Date and will expire 12 months after the Initial Exercise Date. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 19:27 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Share Warrants (Right to Buy) · Derivative | 2,119 | Not disclosed Strike: $1.50 | Not disclosed |
DisclosureSEC source: 0001654954-22-014747 · section16.xml · derivative · entry 2 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,119 Underlying: Common Shares · 2,119 shares Expires not disclosed F2 · security: Consists of Class A Warrants to purchase Common Shares.The Class A Warrants are exercisable on the date that is the earlier to occur of 60 days from the closing date of the offering and the date a Registration Statement covering the resale of the Common Shares and Common Shares issuable upon exercise of the Warrants is declared effective (the "Initial Exercise Date") and will expire three years after the Initial Exercise Date. F1 · price: The reported securities are included within 4,239 Common Shares purchased by the reporting person for $1.1250 per Common Share. Each Common Share includes the purchase of one-half of a Class A Warrant to purchase one Common Share, and one-half of a Class B Warrant to purchase one Common Share. F2 · derivative.exercise_date: Consists of Class A Warrants to purchase Common Shares.The Class A Warrants are exercisable on the date that is the earlier to occur of 60 days from the closing date of the offering and the date a Registration Statement covering the resale of the Common Shares and Common Shares issuable upon exercise of the Warrants is declared effective (the "Initial Exercise Date") and will expire three years after the Initial Exercise Date. F2 · derivative.expiration_date: Consists of Class A Warrants to purchase Common Shares.The Class A Warrants are exercisable on the date that is the earlier to occur of 60 days from the closing date of the offering and the date a Registration Statement covering the resale of the Common Shares and Common Shares issuable upon exercise of the Warrants is declared effective (the "Initial Exercise Date") and will expire three years after the Initial Exercise Date. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 19:27 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 4,239 | $1.13 | $4,768.88 |
DisclosureSEC source: 0001654954-22-014747 · section16.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,480 F1 · price: The reported securities are included within 4,239 Common Shares purchased by the reporting person for $1.1250 per Common Share. Each Common Share includes the purchase of one-half of a Class A Warrant to purchase one Common Share, and one-half of a Class B Warrant to purchase one Common Share. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 15:23 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 3,000 | $1.49 | $4,482.90 |
DisclosureSEC source: 0001654954-22-009005 · section16.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,241 Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 12:30 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 3,000 | $1.61 | $4,816.50 |
DisclosureSEC source: 0001654954-22-008536 · section16.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,241 Read SEC document |
| May 25, 2022 Filed May 26, 2022 16:29 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 3,500 | $1.74 | $6,090.00 |
DisclosureSEC source: 0001654954-22-007559 · section16.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,241 Read SEC document |
| March 14, 2022 Filed Mar 15, 2022 16:44 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 1,250 | $2.79 | $3,486.63 |
DisclosureSEC source: 0001654954-22-003144 · section16.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,741 Read SEC document |
| March 10, 2022 Filed Mar 11, 2022 16:10 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 1,000 | $3.22 | $3,222.90 |
DisclosureSEC source: 0001654954-22-002936 · section16.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,491 Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 16:06 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 1,250 | $2.90 | $3,621.88 |
DisclosureSEC source: 0001654954-22-002765 · section16.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,491 Read SEC document |
| February 28, 2022 Filed Mar 8, 2022 00:40 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock Option (right to buy) · Derivative | 43,500 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001654954-22-002653 · section16.xml · derivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,500 Underlying: Common Shares · 43,500 shares Expires 2032-02-28 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 36 months beginning on the Grant Date. Read SEC document |
| April 22, 2021 Filed Apr 26, 2021 21:00 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001654954-21-004632 · section16.xml · derivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Shares · 80,000 shares Expires 2031-04-22 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 36 months beginning on the Grant Date. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 15:44 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 3,500 | $5.19 | $18,165.00 |
DisclosureSEC source: 0001654954-21-003333 · section16.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,241 Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 18:56 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon stock | 4,500 | $5.08 | $22,860.00 |
DisclosureSEC source: 0001654954-21-003279 · section16.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,741 Read SEC document |
| November 06, 2020 Filed Nov 9, 2020 20:39 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | OtherCommon Share Warrants (Right to Buy) · Derivative | 914 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001654954-20-012001 · section16.xml · derivative · entry 2 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 914 shares Expires 2020-11-08 Read SEC document |
| November 06, 2020 Filed Nov 9, 2020 20:39 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | OtherCommon Shares | 914 | $4.00 | $3,656.00 |
DisclosureSEC source: 0001654954-20-012001 · section16.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,241 Read SEC document |
| October 13, 2020 Filed Oct 14, 2020 19:57 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $7.44 | $0.00 |
DisclosureSEC source: 0001654954-20-011151 · section16.xml · derivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common shares · 50,000 shares Expires 2030-10-13 F1 · derivative.exercise_date: This option vests monthly in equal proportions over 36 months beginning on the Grant Date. Read SEC document |
| May 27, 2020 Filed May 29, 2020 13:20 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 1,000 | $3.00 | $3,000.00 |
DisclosureSEC source: 0001654954-20-006075 · section16.xml · nonDerivative · entry 2 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,327 Read SEC document |
| May 27, 2020 Filed May 29, 2020 13:20 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 1,500 | $3.00 | $4,498.50 |
DisclosureSEC source: 0001654954-20-006075 · section16.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,327 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:19 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantShare Option (Right to Buy) · Derivative | 68,988 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001654954-20-001654 · section16.xml · derivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,988 Underlying: Common Shares · 68,988 shares Expires 2030-02-12 F1 · derivative.exercise_date: 33% vested on 2/12/2020, with a prorata amount of the balance vesting monthly thereafter over the next 36 months until fully vested Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 19:09 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Share Warrants (Right to Buy) · Derivative | 914 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001654954-20-000265 · section16.xml · derivative · entry 3 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 914 Underlying: Common Shares · 914 shares Expires 2020-11-08 F3 · security: Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020. F1 · price: The reported securities are included within 1,371 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 19:09 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Share Warrants (Right to Buy) · Derivative | 1,371 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001654954-20-000265 · section16.xml · derivative · entry 2 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,371 Underlying: Common Shares · 1,371 shares Expires 2023-07-08 F2 · security: Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023. F1 · price: The reported securities are included within 1,371 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 19:09 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | PurchaseCommon Shares | 1,827 | $4.11 | $7,508.97 |
DisclosureSEC source: 0001654954-20-000265 · section16.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,827 F1 · price: The reported securities are included within 1,371 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. Read SEC document |
| January 08, 2020 Filed Jan 13, 2020 13:31 UTC Amendment | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Share Warrants (Right to Buy) · Derivative | 914 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001654954-20-000338 · section16.xml · derivative · entry 3 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 914 Underlying: Common Shares · 914 shares Expires 2020-11-08 F3 · security: Consists of Class B Warrants to purchase Common Shares. The Class B Warrants are exercisable beginning on July 8, 2020 and expire on November 8, 2020. F4 · kind: Amended to reflect acquisition from the issuer. F1 · price: The reported securities are included within 1,827 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. Read SEC document |
| January 08, 2020 Filed Jan 13, 2020 13:31 UTC Amendment | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Share Warrants (Right to Buy) · Derivative | 1,371 | Not disclosed Strike: $4.80 | Not disclosed |
DisclosureSEC source: 0001654954-20-000338 · section16.xml · derivative · entry 2 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,371 Underlying: Common Shares · 1,371 shares Expires 2023-07-08 F2 · security: Consists of Class A Warrants to purchase Common Shares. The Class A Warrants are exercisable beginning on July 8, 2020 and expire on July 8, 2023. F4 · kind: Amended to reflect acquisition from the issuer. F1 · price: The reported securities are included within 1,827 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. Read SEC document |
| January 08, 2020 Filed Jan 13, 2020 13:31 UTC Amendment | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 1,827 | $4.11 | $7,508.97 |
DisclosureSEC source: 0001654954-20-000338 · section16.xml · nonDerivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,827 F4 · kind: Amended to reflect acquisition from the issuer. F1 · price: The reported securities are included within 1,827 Common Shares purchased by the reporting person for $4.11 per Common Share. Each Common Share includes the purchase of Class A Warrants to purchase 0.75 of a Common Share, and Class B Warrants to purchase 0.50 of a Common Share. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 22:31 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock Option (right to buy) · Derivative | 91 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001779126-19-000003 · primary_doc.xml · derivative · entry 3 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,620 Underlying: Common Shares · 91 shares Expires 2028-12-28 F1 · derivative.exercise_price: In Canadian currency. F2 · shares: Represents additional options to purchase common stock of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) (the "Issuer") issued pursuant to the post-closing adjustment contemplated by that certain Share Exchange Agreement, dated as of March 7, 2019, by and among the Issuer, Edesa Biotech, Inc. ("Edesa"), and the shareholders of Edesa. The closing of the share exchange transaction contemplated by the Share Exchange Agreement occurred on June 7, 2019, at which time the Issuer acquired all the outstanding capital shares of Edesa from the Edesa shareholders. This option was issued in replacement of an option to purchase shares of Edesa. F3 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F6 · derivative.exercise_date: This option vests and becomes exercisable 1/3 on December 28, 2019, and monthly thereafter through December 28, 2021. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 22:31 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock Option (right to buy) · Derivative | 1,365 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001779126-19-000003 · primary_doc.xml · derivative · entry 2 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,299 Underlying: Common Shares · 1,365 shares Expires 2027-09-26 F1 · derivative.exercise_price: In Canadian currency. F2 · shares: Represents additional options to purchase common stock of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) (the "Issuer") issued pursuant to the post-closing adjustment contemplated by that certain Share Exchange Agreement, dated as of March 7, 2019, by and among the Issuer, Edesa Biotech, Inc. ("Edesa"), and the shareholders of Edesa. The closing of the share exchange transaction contemplated by the Share Exchange Agreement occurred on June 7, 2019, at which time the Issuer acquired all the outstanding capital shares of Edesa from the Edesa shareholders. This option was issued in replacement of an option to purchase shares of Edesa. F3 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F5 · derivative.exercise_date: This option vests and becomes exercisable 1/3 on September 26, 2018, and monthly thereafter through September 26, 2020. Read SEC document |
| July 26, 2019 Filed Jul 30, 2019 22:31 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock Option (right to buy) · Derivative | 7,663 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001779126-19-000003 · primary_doc.xml · derivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,416 Underlying: Common Shares · 7,663 shares Expires 2027-08-28 F1 · derivative.exercise_price: In Canadian currency. F2 · shares: Represents additional options to purchase common stock of Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) (the "Issuer") issued pursuant to the post-closing adjustment contemplated by that certain Share Exchange Agreement, dated as of March 7, 2019, by and among the Issuer, Edesa Biotech, Inc. ("Edesa"), and the shareholders of Edesa. The closing of the share exchange transaction contemplated by the Share Exchange Agreement occurred on June 7, 2019, at which time the Issuer acquired all the outstanding capital shares of Edesa from the Edesa shareholders. This option was issued in replacement of an option to purchase shares of Edesa. F3 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F4 · derivative.exercise_date: This option was fully vested on August 28, 2017. Read SEC document |
| June 07, 2019 Filed Jun 12, 2019 00:22 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock Option (right to buy) · Derivative | 1,529 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001779126-19-000002 · primary_doc.xml · derivative · entry 3 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,529 Underlying: Common Shares · 1,529 shares Expires 2028-12-28 F1 · derivative.exercise_price: In Canadian currency. F2 · shares: On June 7, 2019, Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) completed its share exchange transaction with Edesa Biotech Inc. ("Edesa") and the shareholder of Edesa pursuant to that certain Share Exchange Agreement, dated March 7, 2019. This option was issued in replacement of an option to purchase shares of Edesa. F3 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F6 · derivative.exercise_date: This option vests and becomes exercisable 1/3 on 12/28/19, and monthly thereafter through 12/28/21. Read SEC document |
| June 07, 2019 Filed Jun 12, 2019 00:22 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock Option (right to buy) · Derivative | 22,934 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001779126-19-000002 · primary_doc.xml · derivative · entry 2 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,934 Underlying: Common Shares · 22,934 shares Expires 2027-09-26 F1 · derivative.exercise_price: In Canadian currency. F2 · shares: On June 7, 2019, Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) completed its share exchange transaction with Edesa Biotech Inc. ("Edesa") and the shareholder of Edesa pursuant to that certain Share Exchange Agreement, dated March 7, 2019. This option was issued in replacement of an option to purchase shares of Edesa. F3 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F5 · derivative.exercise_date: This option vests and becomes exercisable 1/3 on 9/26/18, and monthly thereafter through 9/26/20. Read SEC document |
| June 07, 2019 Filed Jun 12, 2019 00:22 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantStock Option (right to buy) · Derivative | 128,753 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001779126-19-000002 · primary_doc.xml · derivative · entry 1 Brooks Michael J · CIK 0001779126 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,753 Underlying: Common Shares · 128,753 shares Expires 2027-08-28 F1 · derivative.exercise_price: In Canadian currency. F2 · shares: On June 7, 2019, Edesa Biotech, Inc. (formerly known as Stellar Biotechnologies, Inc.) completed its share exchange transaction with Edesa Biotech Inc. ("Edesa") and the shareholder of Edesa pursuant to that certain Share Exchange Agreement, dated March 7, 2019. This option was issued in replacement of an option to purchase shares of Edesa. F3 · shares: All share numbers and exercise prices reflect the 1-for-6 reverse split of the Issuer's common shares which occurred on June 7, 2019. F4 · derivative.exercise_date: This option was fully vested on 8/28/17. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.